For the quarter ending 2026-03-31, ACAD had $104,518K increase in cash & cash equivalents over the period. $28,769K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 3,637 | 273,568 | 71,779 | 45,653 |
| Stock-based compensation | 14,698 | 13,235 | 13,180 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | 453 | 670 | 1,102 | 3,652 |
| Amortization of intangible assets | 2,722 | 2,722 | 2,723 | 5,444 |
| Gain on sale of non-financial asset | - | 0 | - | - |
| Gain on strategic investment | - | 0 | - | - |
| Depreciation | 271 | 202 | 227 | 442 |
| Loss on sale of investment securities | - | 0 | - | - |
| Deferred income taxes | -94 | -249,879 | - | - |
| Accounts receivable, net | 13,893 | 5,607 | 8,345 | 8,766 |
| Interest and other receivables | -13,740 | 3,192 | 11,401 | 6,225 |
| Inventory | -78 | 4,892 | -1,248 | 14,553 |
| Prepaid expenses | -113 | - | 8,121 | -2,934 |
| Prepaid expenses and other current assets | - | 3,845 | - | - |
| Other assets | 32 | 850 | 700 | 1,306 |
| Operating lease right-of-use assets | -2,164 | -2,196 | -2,212 | -4,259 |
| Accounts payable | 1,343 | -10,844 | 1,650 | 3,905 |
| Accrued liabilities | 23,557 | -68,391 | 27,776 | 21,350 |
| Operating lease liabilities | -2,183 | -2,919 | -2,179 | -1,418 |
| Long-term liabilities | -6,500 | 5,248 | -14,659 | 10,492 |
| Net cash provided by operating activities | 33,981 | -48,731 | 74,288 | 84,279 |
| Purchases of investment securities | 15,007 | 157,614 | 204,553 | 330,398 |
| Sale and maturity of investment securities | 86,500 | 105,750 | 125,589 | 262,190 |
| Proceeds from sale of non-financial asset | - | 0 | - | - |
| Proceeds from sales of strategic investment | - | 0 | - | - |
| Payment of milestone and contingent payments in connection with asset acquisition | 0 | 0 | 0 | 98,838 |
| Purchases of property and equipment | 5,212 | 4,005 | 388 | 297 |
| Net cash provided by (used in) investing activities | 66,281 | -55,869 | -79,352 | -167,343 |
| Proceeds from issuance of common stock, net of issuance costs | 4,231 | 22,666 | 9,423 | 17,794 |
| Net cash provided by financing activities | 4,231 | 22,666 | 9,423 | 17,794 |
| Effect of exchange rate changes on cash | 25 | 7 | 0 | 19 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 104,518 | -81,927 | 4,359 | -65,251 |
| Beginning of period | 185,540 | 60,892 | 328,359 | - |
| End of period | 290,058 | -81,927 | 267,467 | - |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)